P/B
4,3
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
$3.8B
Market Cap • 11/10/2026
2019
(7 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
11,9
EPS
—
Market Cap
Market Cap
3,8B
EV
2,9B
EV/Revenue
0
EV/EBITDA
-21,3
EV/EBIT
-21,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-12,6%
Total Yield
-12,6%
Payout
0%
Retained Earnings
-431M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
-125,3%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
0,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
22,7%
CAGR Net Income 5Y
18,5%
CAGR EPS 5Y
-29,4%
CAGR OCF 5Y
9,2%
Leverage
N.D./EBITDA
6,5
Debt/Equity
0%
Current Ratio
45,9
Quick Ratio
45,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!